BridgeBio have significantly improved the course of the new therapy for ATTR-CM, utilizing the investigational drug. Early clinical data reveals potential improvements for patients diagnosed by the debilitating https://attrcm433727.designi1.com/62851080/company-advances-cardiac-amyloidosis-management-with-the-therapy